Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2195 |
---|---|
High | 0.2218 |
Low | 0.2055 |
Bid | 0.2075 |
Offer | 0.23 |
Previous close | 0.2195 |
Average volume | 832.14k |
---|---|
Shares outstanding | 10.36m |
Free float | 10.36m |
P/E (TTM) | -- |
Market cap | 2.27m USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:51 BST.
More ▼
Announcements
- SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
- SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
- SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
- SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
- SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
- SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
- SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
More ▼